Capstone Therapeutics announced consolidated earnings results for the year ended December 31, 2013. For the year, the company reported net loss attributable to stock holders of $3,921,000 or $0.10 basic and diluted per share compared to net loss attributable to stock holders of $3,580,000 or $0.09 basic and diluted per share of prior year. Loss from continuing operations was $4,114,000 against $4,053,000 of prior year.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.2 USD | -.--% | -.--% | -.--% |
Apr. 01 | Capstone Holding Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | Capstone Holding Corp. Announces Change in Board of Directors | CI |
1st Jan change | Capi. | |
---|---|---|
-.--% | 820K | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- CAPS Stock
- News Capstone Holding Corp.
- Capstone Therapeutics Announces Consolidated Earnings Results for the Year Ended December 31, 2013